Director, Clinical Pharmacology & Pharmacometrics
AbbVie Inc
Matthew Rosebraugh received his BS degree in pharmaceutical science from Drake University and his doctorate in Pharmacy (Pharmacokinetics) from the University of Iowa, School of Pharmacy. His Ph.D. work focused on pharmaceutical alternatives to blood transfusions for preterm infants. Dr. Rosebraugh joined Abbott/AbbVie in 2012 and has led clinical pharmacology programs for over 20 compounds in the neuroscience, immunology and renal disease therapeutic areas. Dr. Rosebraugh has published many peer-reviewed manuscripts and has presented at numerous scientific conferences. He also is an inventor of patents related to the elezanumab and the foslevodopa/foscarbidopa program. Dr. Rosebraugh is an expert in early phase clinical study designs, data analysis and pharmacokinetic modeling and simulation. Most recently has contributed to regulatory submissions for Duodopa and foslevodopa/foscarbidopa in Parkinson’s disease.
Symposium 8: Use of Real-time Simulation for Decision Making in Clinical Pharmacology
Monday, September 11, 2023
1:30 PM - 5:00 PM PT
Disclosure(s): Abbvie: Employment (), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) ()
1 - Use of Adaptive Graphics Simulations for Device Selection in Parkinson’s Disease
Monday, September 11, 2023
1:30 PM - 5:00 PM PT
Disclosure(s): Abbvie: Employment (), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) ()